Deals > All

France Monaco Central France Eastern France Northern France Paris (region) Southern France Western France

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1646 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Deal: Collaboration or Financing	Date
Bureau Veritas–SGS: investment, 202501– confirmed merger discussion	2025-01-15
Bioptimus–Boom Capital Ventures: investment, 202501 financing round totalling $41m incl co-investor Boom Capital Ventures	2025-01-14
Bioptimus–Cathay Capital: investment, 202501 financing round totalling $41m incl existing + lead investor Cathay Innovation	2025-01-14
Bioptimus–France (govt): investment, 202501 financing round totalling $41m incl existing + co-investor Bpifrance Large Venture Fund	2025-01-14
Bioptimus–Hitachi: investment, 202501 financing round totalling $41m incl co-investor Hitachi Ventures	2025-01-14
Bioptimus–New York Life: investment, 202501 financing round totalling $41m incl co-investor Andera Partners	2025-01-14
Bioptimus–PERSON: investment, 202501 financing round totalling $41m incl angel entrepreneurs Emmanuel Cassimatis	2025-01-14
Bioptimus–PERSON: investment, 202501 financing round totalling $41m incl angel entrepreneurs Thomas Wolf	2025-01-14
Bioptimus–Pomifer Capital: investment, 202501 financing round totalling $41m incl co-investor Pomifer Capital	2025-01-14
Bioptimus–SEVERAL: investment, 202501 financing round $41m led by Cathay Innovation	2025-01-14
Bioptimus–Sofinnova: investment, 202501 financing round totalling $41m incl existing +co-investor Sofinnova Partners	2025-01-14
Bioptimus–Sunrise: investment, 202501 financing round totalling $41m incl co-investor Sunrise	2025-01-14
IBA Lifesciences–Cube Biotech: investment, 202501 acquisition of IBA Lifesciences by Cube Biotech backed by majority owner Archimed	2025-01-13
Normunity–Sanofi: investment, 202501 financing round Series B totalling $75m incl existing + co-investor Sanofi Ventures	2025-01-13
Normunity–SEVERAL: investment, 202501 financing round Series B $75m co-led by Samsara BioCapital + Enavate Sciences	2025-01-13
SpinChip Diagnostics–Mérieux: investment, 202501– acquisition of remaining 80% of SpinChip for €111m in cash by bioMérieux	2025-01-13
Coave Therapeutics–Eurazeo: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Kurma Partners	2025-01-09
Coave Therapeutics–France (govt): investment, 202501 financing round Series A totalling €32m incl co-lead investor Bpifrance InnoBio	2025-01-09
Coave Therapeutics–Fund+: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Fund+	2025-01-09
Coave Therapeutics–Invus Group: investment, 202501 financing round Series A totalling €32m incl new + co-investor Invus	2025-01-09
Coave Therapeutics–Novo Group: investment, 202501 financing round Series A totalling €32m incl co-lead investor Novo Holdings	2025-01-09
Coave Therapeutics–Omnes Capital: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Omnes Capital	2025-01-09
Coave Therapeutics–Seroba: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Seroba Life Sciences	2025-01-09
Coave Therapeutics–SEVERAL: investment, 202501 financing round Series A €32m co-led by Novo Holdings + Bpifrance InnoBio	2025-01-09
Coave Therapeutics–Turenne: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Turenne Capital	2025-01-09
Coave Therapeutics–UI Investissement: investment, 202501 financing round Series A totalling €32m incl new + co-investor UI Investissement	2025-01-09
Tromp Medical–Gilde Investment: investment, 202412 investment by new investor Gilde Healthcare	2024-12-16
Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments	2024-12-12
Aqemia–Cathay Capital: investment, 202412 financing round totalling $38m incl new + lead investor Cathay Innovation	2024-12-10
Aqemia–Elaia Partners: investment, 202412 financing round totalling $38m incl existing + co-investor Elaia	2024-12-10
Aqemia–Eurazeo: investment, 202412 financing round totalling $38m incl existing + co-investor Eurazeo	2024-12-10
Aqemia–France (govt): investment, 202412 financing round totalling $38m incl existing + co-investor Bpifrance Large Venture	2024-12-10
Aqemia–SEVERAL: investment, 202412 financing round $38m led by new investor Cathay Innovation	2024-12-10
Aqemia–Wendel: investment, 202412 financing round totalling $38m incl existing + co-investor Wendel	2024-12-10
Citryll–SEVERAL: investment, 202412 financing round Series B €85m co-led by JnJ JJDC + Forbion + Novartis Venture Fund	2024-12-09
Andera Partners–MC Services: public relations, 202411 service existent by MC Services	2024-11-13
Alentis Therapeutics–France (govt): investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor Bpifrance InnoBio 2 Fund	2024-11-12
Alentis Therapeutics–Jeito Capital: investment, 202411 financing round Series D totalling $181.4m incl existing + co-lead investor Jeito Capital	2024-11-12
Alentis Therapeutics–SEVERAL: investment, 202411 financing round Series D $181.4m led by OrbiMed with co-leads Novo Holdings + Jeito Capital	2024-11-12
Mediaire–LBO France: investment, 202411 financing round totalling €12m incl lead investor LBO France	2024-11-12
Mediaire–SEVERAL: investment, 202411 financing round €12m led by LBO France	2024-11-12
Inverna Therapeutics–Argobio: investment, 202410 investment by founding investor Argobio	2024-10-22
Bureau Veritas–Mérieux: investment, 202410– acquisition €360m of global food testing of Bureau Veritas by Mérieux NutriSciences	2024-10-07
Kurma–SEVERAL: investment, 202410 first closing of Kurma Biofund IV with target for final closing of €250m	2024-10-03
Sequentia Biotech–BPCE: investment, 202409 financing round Series A totalling €10m incl lead investor Seventure Partners	2024-09-27
Sequentia Biotech–SEVERAL: investment, 202409 financing round Series A €10m with Seventure Partners + EIC Fund	2024-09-27
Genespire–SEVERAL: investment, 202409 financing round Series B €46.6m led by Sofinnova Partners + Xgen Venture + CDP Venture Capital	2024-09-25
Genespire–Sofinnova: investment, 202409 financing round Series B totalling €46.6m incl existing + co-lead investor Sofinnova Partners	2024-09-25
Symphera–IRCAD: investment, 202409 seed financing round totalling €2.4m incl co-investor IRCAD Strasbourg	2024-09-16
Symphera–SEVERAL: investment, 202409 seed financing round €2.4m led by HTGF	2024-09-16
Abolis Biotechnologies–Clay Capital: investment, 202409 financing round totalling €35m incl investor Clay Capital	2024-09-12
Abolis Biotechnologies–Evonik: investment, 202409 financing round totalling €35m incl investor Evonik Venture Capital	2024-09-12
Abolis Biotechnologies–Germany (govt): investment, 202409 financing round totalling €35m incl investor DeepTech & Climate Fonds	2024-09-12
Abolis Biotechnologies–Icos Capital: investment, 202409 financing round totalling €35m incl investor Icos Capital	2024-09-12
Abolis Biotechnologies–Liberset: investment, 202409 financing round totalling €35m incl investor Liberset	2024-09-12
Abolis Biotechnologies–L’Oréal: investment, 202409 financing round totalling €35m incl investor BOLD	2024-09-12
Abolis Biotechnologies–SEVERAL: investment, 202409 financing round €35m with BOLD L’Oréal VC Fund + Evonik Venture Capital et al	2024-09-12
Novameat–SEVERAL: investment, 202409 financing round Series A €17.4m led by Sofinnova Partners + Forbion BioEconomy Fund	2024-09-12
Novameat–Sofinnova: investment, 202409 financing round Series A totalling €17.4m incl new + co-lead investor Sofinnova Partners	2024-09-12
Sofinnova–Optimum Strategic Communications: public relations, 202409 service existent by Optimum for Sofinnova Partners	2024-09-10
Caresyntax–SEVERAL: credit, 202408 up to $100m growth debt facility	2024-08-15
Caresyntax–SEVERAL: investment, 202408 financing round Series C extension $80m	2024-08-15
Balderton Capital–SEVERAL: investment, 202408 announced $615m Early Stage Fund IX	2024-08-12
Balderton Capital–SEVERAL: investment, 202408 announced $685m Growth Fund II	2024-08-12
Exscientia–Recursion Pharmaceuticals: investment, 202408– merger announced with former Recursion shareholders holding 74% of combined company	2024-08-08
Bruker–Novalix: drug discovery technology, 202408– strategic collab to enable new paradigms in drug discovery	2024-08-07
Novalix–Bruker: investment, 202408 strategic minority investment €na by Bruker	2024-08-07
Carbios–MC Services: public relations, 202408 service existent MC Services Is media contact for DACH + UK	2024-08-06
FCC Group–Carbios: PET biorecycling, 202408– letter of intent to study implementation of Carbios technology at UK-based plant of FCC Environment UK	2024-08-06
Nestlé–Seres Therapeutics: microbiome-based drug, 202408– acquisition of Vowst (SER-109) assets for up to $488.5m by Nestlé Health Science	2024-08-06
Seres Therapeutics–Nestlé: investment, 202408– equity investment $15m acquisition 14.3m shares common stock at $1.05/share by Nestlé	2024-08-06
Deepc–SEVERAL: investment, 202407 financing round Series A extension €13m led by Sofinnova Partners + Bertelsmann Investments	2024-07-25
Deepc–Sofinnova: investment, 202407 financing round Series A extension totalling €13m incl existing + co-lead investor Sofinnova Partners	2024-07-25
Micropep Technologies–BPI Green Tech Investment: investment, 202407 financing round Series B totalling $29m co-led by new investor BPI GTI	2024-07-25
Micropep Technologies–SEVERAL: investment, 202407 financing round Series B $29m led by Zebra Impact Ventures + BPI Green Tech Investment	2024-07-25
Micropep Technologies–Z Impact Ventures: investment, 202407 financing round Series B totalling $29m co-led by new investor Zebra Impact Ventures	2024-07-25
Axa–Zyme Communications: public relations, 202406 service existent for Kadans Science Partner by Zyme	2024-07-24
Asceneuron–SEVERAL: investment, 202407 financing round Series C $100m led by Novo Holdings	2024-07-16
Asceneuron–Sofinnova: investment, 202407 financing round Series C totalling $100m incl existing + co-investor Sofinnova Partners	2024-07-16
Catalym–Canaan Partners: investment, 202407 financing round Series D totalling $150m incl new + co-lead investor Canaan Partners	2024-07-16
Catalym–Jeito Capital: investment, 202407 financing round Series D totalling $150m incl existing + co-investor Jeito Capital	2024-07-16
Catalym–SEVERAL: investment, 202407 financing round Series D $150m led by Canaan Partners + Bioqube Ventures	2024-07-16
Affluent Medical–Edwards Lifesciences: investment, 202407 capital increase totalling €8.54m incl €5m from Edwards LS resulting in 9.21% shareholding	2024-07-12
Affluent Medical–MC Services: public relations, 202407 service existent MC Services Is Media Contact for Europe	2024-07-12
Affluent Medical–SEVERAL: investment, 202407 capital increase €8.54m with 6.19m new shares at €1.38/share led by Edwards Lifesciences	2024-07-12
Ipsen–Foreseen Biotechnology: antibody-drug conjugate, 202407– license ww excl to FS001 up to $1.03b	2024-07-11
Endoron Medical–SEVERAL: investment, 202407 financing round Series A $10m led by Sofinnova Partners	2024-07-09
SciRhom–Andera Partners: investment, 202407 financing round Series A totalling €63m incl co-lead investor Andera Partners	2024-07-09
SciRhom–Eurazeo: investment, 202407 financing round Series A totalling €63m incl co-lead investor Kurma Partners	2024-07-09
SciRhom–SEVERAL: investment, 202407 financing round Series A €63m	2024-07-09
Myricx Pharma–SEVERAL: investment, 202407 financing round Seires A £90m led by Novo Holidngs + Abingworth	2024-07-08
Myricx Pharma–Sofinnova: investment, 202407 financing round Seires A totalling £90m incl existing + co-investor Sofinnova Partners	2024-07-08
Pentixapharm–MC Services: public relations, 202407 service existent by MC Services	2024-07-03
CatSci–Keensight Capital: investment, 202406 additional investment? by Keensight to support acquisition of Reach Separations by CatSci	2024-06-25
Reach Separations–CatSci: investment, 202406 acqusition of Reach Separations by CatSci Ltd with support from Keensight Capital	2024-06-25
Adcytherix–Bellevue: investment, 202406 seed financing round totalling €30m incl co-investor Pureos Bioventures	2024-06-11
Adcytherix–KKR: investment, 202406 seed financing round totalling €30m incl co-investor Dawn Biopharma	2024-06-11
Adcytherix–OTHER: investment, 202406 seed financing round totalling €30m incl participation from management	2024-06-11
Adcytherix–Pontifax: investment, 202406 seed financing round totalling €30m incl lead investor Pontifax Venture Capital	2024-06-11
Adcytherix–RA Capital: investment, 202406 seed financing round totalling €30m incl co-investor RA Capital Management	2024-06-11

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)